Capricor Therapeutics Inc Stock Price, News & Analysis

Capricor Therapeutics announced positive outcomes from the HOPE-2 trial for CAP-1002, demonstrating significant improvements in Duchenne muscular dystrophy (DMD) patients. The trial met its primary efficacy endpoint of mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01), with additional positive results in skeletal and cardiac functions. CAP-1002 slowed the decline of muscle function by 71% over one year, with significant cardiac improvements (p=0.002). The findings were presented at the World Muscle Society Annual Meeting, indicating potential for advancing into pivotal trials.

Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán, Ph.D., will present at two upcoming conferences: the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, from 9:20 to 9:50 a.m. (ET) and the Cell & Gene Meeting on the Mesa on October 13, 2021, from 3:30 to 3:45 p.m. (PT) in Carlsbad, CA. Capricor focuses on developing transformative cell and exosome-based therapeutics, including its lead candidate CAP-1002, currently in clinical trials for Duchenne muscular dystrophy and COVID-19 treatment.

Capricor Therapeutics (NASDAQ: CAPR) will present at the 23rd Annual Global Investment Conference hosted by H.C. Wainwright from September 13-15, 2021. The company's CEO, Linda Marbán, Ph.D., will deliver an on-demand presentation available starting 7:00 a.m. ET on September 13. An archived version will be accessible post-conference on Capricor's website. Additionally, management plans to hold one-on-one meetings with institutional investors during the event.

Capricor focuses on cell and exosome-based therapeutics for various diseases, including its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19.

Capricor Therapeutics (NASDAQ: CAPR) is set to present final data from its HOPE-2 clinical trial for CAP-1002 at the World Muscle Society Virtual Congress on Sept. 24, 2021. The trial focused on late-stage Duchenne muscular dystrophy (DMD) with 80% of participants being non-ambulant. CEO Dr. Linda Marbán expressed optimism about the data supporting CAP-1002's role in DMD treatment. The trial involved 20 patients across nine U.S. sites, and the session is scheduled from 4:15 to 5 p.m. BST (11:15 a.m. to 12 p.m. EST).

Capricor Therapeutics (NASDAQ: CAPR) reported significant advancements in its therapy programs for Duchenne muscular dystrophy (DMD) and COVID-19. After a successful end-of-phase-II meeting with the FDA, Capricor plans to initiate a Phase III pivotal trial for CAP-1002 for DMD. Financially, the company achieved approximately $200,000 in revenues, up from $50,000 year-over-year. However, operating expenses rose to $5.3 million, resulting in a net loss of $4.7 million. Their cash reserves increased to $38.1 million, projected to fund operations for at least two years.

Capricor Therapeutics (NASDAQ: CAPR) will release its Q2 2021 financial results on August 12, 2021, after market close. Following this, a webcast and conference call will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics for various diseases, including Duchenne muscular dystrophy and COVID-19 related conditions. The lead candidate, CAP-1002, is currently in clinical development.

Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a study showing that cardiosphere-derived exosomes (CDC-EVs) can reduce kidney damage and enhance blood vessel formation in a preclinical acute trauma model. This research, in collaboration with the USA Army Institute of Surgical Research, indicates CDC-EVs as a potential antishock therapeutic, highlighting their ease of use in field situations. Capricor is also actively enrolling patients in a Phase II study for CAP-1002 to treat severe COVID-19, emphasizing the broader therapeutic potential of their exosome technology.

Capricor Therapeutics (NASDAQ: CAPR) has appointed Karimah Es Sabar to its Board of Directors, effective immediately. With over 35 years of experience in the life sciences industry, Es Sabar brings substantial expertise in business development and strategic collaborations. CEO Linda Marbán expressed optimism about her contributions, citing her successful track record in launching first-in-class vaccines. Capricor focuses on innovative therapies, including its CAP-1002 cell therapy for Duchenne muscular dystrophy and exosome technologies aimed at treating various diseases. This leadership change marks a significant step in Capricor's growth strategy.

Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán will present updates on the Phase II HOPE-2 trial of CAP-1002 at the PPMD 2021 Virtual Annual Conference on June 23. The ongoing open-label extension study allows eligible patients to receive CAP-1002 after completing a year-long trial. The panel will discuss therapies to protect muscles in Duchenne muscular dystrophy, affecting one in 3,600 male births globally. CAP-1002 is currently in development and aims to improve treatment outcomes for this condition.